This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutPatient ProfilesEfficacy & SafetyEfficacy &
SafetyEfficacy & Safety DataPublicationsDosingDosingDosing With All-in-One ReconstitutionManufacturing and PurificationResourcesResourcesMaterialsVideosResources for Patients and CaregiversAdditional Resources
Prescribing InformationIndicationRelated: See information on our hemophilia B product
Resources for Patients and CaregiversPfizer Hemophilia is more than just factor—
It’s support for your eligible patientsPfizer Patient Affairs Liaisons

Pfizer Patient Affairs Liaisons are professionals dedicated to serving the rare disease community by connecting patients, caregivers, and patient advocacy organizations with Pfizer Rare Disease tools and resources. A Patient Affairs Liaison’s work is guided by the principles of compassion, commitment, and connection.

Pfizer Patient Affairs Liaisons are not measured or awarded based on sales performance nor will they ask patients to switch products.

Your patients can find their Pfizer Patient Affairs Liaison at pfizerpal.com.

 Visit pfizerpal.com LoadingXYNTHA Patient Brochure

Educates patients on important information about XYNTHA and available support tools.

 Download now LoadingPfizer Hemophilia ConnectPfizer Hemophilia Connect—A patient's one-stop source for all Pfizer Hemophilia resources and support programs
  • One number with access to all of Pfizer Hemophilia's patient resources and support programs
  • Financial support programs for eligible patients
TitleIf your patients have questions about Pfizer Hemophilia’s resources and support, they can call Pfizer Hemophilia Connect at 1-844-989-HEMO (4366) or visit pfizerhemophiliasupport.comIf you are prescribing XYNTHA, eligible patients may save up to $12,000 per year with the Factor Savings Card*

With the Pfizer Factor Savings Card,† eligible patients who have been prescribed XYNTHA by their health care providers may save up to $12,000 per year toward their co-pay, deductible, and coinsurance costs.

 Learn more LoadingTerms and conditions apply.This card will be accepted only at participating factor suppliers.This coupon is not health insurance.If patients have questions about the use of the Pfizer Factor Savings Card, they can call 1-844-989-HEMO (4366) or send questions to: Pfizer Factor Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. The Factor Savings Card cannot be combined with other offers and is limited to one per person.

Pfizer Hemophilia Factor Savings Card Offer Terms and Conditions

OFFER TERMS: By using the Pfizer Factor Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

Patients are not eligible to use this Card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicaid, Medicare, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Patients must have private insurance. Offer is not valid for cash-paying patients. The value of the Factor Savings Card is limited to $12,000 per calendar year or the amount of your co-pay over 1 year, whichever is less. This Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other health or pharmacy benefit programs. You must deduct the value of this Card from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf. You are responsible for reporting use of the Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required. You should not use the Card if your insurer or health plan prohibits use of manufacturer co-pay cards. This Card is not valid where prohibited by law. The Card cannot be combined with any other savings, free trial, or similar offers for the specified prescription. The Card will be accepted only at participating factor suppliers. If your factor supplier does not participate, you may be able to submit a request for a rebate in connection with this offer. This Card is not health insurance. Offer good only in the United States and Puerto Rico. The Card is limited to 1 per person during this offering period and is not transferable. No other purchase is necessary. Data related to your redemption of the Card may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. Offer expires 12/31/23. No membership fees. Go to PfizerFactorSavingsCard.com and download your card today.

If you have questions, please call 1-844-989-HEMO (4366) or send questions to:
Pfizer Factor Savings Program
2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560

Trial Prescription Program—Start your eligible patients on XYNTHA

With the Trial Prescription Program, patients prescribed XYNTHA for the first time may be eligible to receive a one-time, 1-month trial supply up to 20,000 IU at no cost. This program is available only for first-time use by commercially insured patients. Medicare/Medicaid beneficiaries are not eligible. Terms and conditions apply.

Getting started
  1. Discuss with your patient and determine if XYNTHA is right for him/her.
  2. Review program eligibility terms with your patient. He/she must be covered by a private (commercial) insurance plan.
  3. Download and complete the enrollment and authorization forms. Direct your patient to download the appropriate forms. If the patient has difficulty accessing the form he/she may also contact his/her local Pfizer Hemophilia Patient Affairs Liaison or our hotline number, 1-844-989-HEMO (4366). To enroll, your eligible patient must read the terms and conditions and complete parts 1 to 4 of the form; parts 5 to 13 are to be completed by the physician.
  4. Complete the prescription and submit the forms. Fax the completed form with the prescription and the patient authorization form to 1-888-868-8660. Fax must be sent from a health care provider's office. You may also mail required documents to:

Trial Prescription Program Administrator, MedVantx
PO Box 5736
Sioux Falls, SD 57117-5736

Please note that processing and delivery may take 1 to 3 weeks after the submission of the form.

For any questions about completing the Factor Product Trial Prescription Program application, please call 1-844-989-HEMO (4366), Monday through Friday, 9:00 AM to 5:00 PM ET for more information.

OFFER TERMS: By enrolling in the 1-month trial program for Pfizer Factor Product, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

You (the patient) are currently covered by a private (commercial) insurance plan. The patient, or health care provider on the patient’s behalf, must provide a completed enrollment form and a valid prescription to the Pfizer Factor Product Trial Prescription Program. The program is valid for one 1-month trial of up to 20,000 IU of factor. Trial cannot exceed 30 days. The patient, or the health care provider on the patient’s behalf, must not submit any claim for reimbursement for product dispensed pursuant to this program to any third-party payor, including Medicaid, Medicare, or any other federal or state health care program. The patient must not apply the value of the free product received through this program toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP). The free trial offer is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs. Patients who have already begun therapy with or who have been treated with Pfizer Factor Product are not eligible to participate in the program. Only new patients may use this offer. Only 1 program enrollment per person per lifetime. By redeeming this offer, you certify that you are not currently using Pfizer Factor Product. Program not available where prohibited by law. This free trial is not health insurance. This program cannot be combined with any other savings, free trial, or similar offers for the specified prescription. The free trial offer will only be accepted by participating factor providers. Offer good only in the United States and Puerto Rico. This offer is not transferable. Pfizer reserves the right to rescind, revoke, or amend this free trial program without notice. No membership fees. For questions about the Pfizer Factor Product Trial Prescription Program, please call 1-844-989-HEMO (4366) or write to us at Pfizer Factor Product Trial Prescription Program Administrator, MedVantx, PO Box 5736, Sioux Falls, SD 57117-5736.Resources

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-XYN-USA-0504
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
INDICATION XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes.  XYNTHA is not indicated in patients with von Willebrand’s disease. 

Please see full  Prescribing Information  for XYNTHA and  XYNTHA SOLOFUSE.

Important Safety Information
  • Do not use in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins.
  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA. Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. Discontinue XYNTHA if hypersensitivity symptoms occur and administer appropriate emergency treatment. XYNTHA contains trace amounts of hamster proteins. Patients may develop hypersensitivity to these proteins.
  • Inhibitors have been reported following administration of XYNTHA. Monitor patients for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • Clinical response to XYNTHA may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XYNTHA sufficient to achieve clinical response. If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.
  • Across all studies, the most common adverse reactions (≥10%) with XYNTHA in previously treated adult and pediatric patients were headache (24% of subjects), arthralgia (23%), fever (23%), and cough (12%). Other adverse reactions reported in ≥5% of subjects were diarrhea, vomiting, and weakness.
  • XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Patients should be advised that local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.
Indication

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

XYNTHA is not indicated in patients with von Willebrand’s disease.

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.